FDA Announces Public Advisory Committee Meeting for Atropine Sulfate Ophthalmic Solution NDA 219694

Summary

The Food and Drug Administration (FDA) is announcing a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee) to discuss a New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%. The Committee will provide recommendations on the application.